ISRCTN29775286 https://doi.org/10.1186/ISRCTN29775286

# The effect of rofecoxib on colorectal liver metastases

| Submission date | Recruitment status | [_] Prospectively registered |
|---|---|---|
| 01/07/2001 | No longer recruiting | [_] Protocol |
| **Registration date** | **Overall study status** | [_] Statistical analysis plan |
| 01/07/2001 | Completed | [X] Results |
| **Last Edited** | **Condition category** | [_] Individual participant data |
| 04/01/2012 | Cancer | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr - -

**Contact details**
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**
CRC COX2

## Study information

## Scientific Title

## Study objectives
Not provided at time of registration

## Ethics approval required
Old ethics approval format

## Ethics approval(s)
Not provided at time of registration

## Study design
Randomised controlled trial

## Primary study design
Interventional

## Secondary study design
Randomised controlled trial

## Study setting(s)
Hospital

## Study type(s)
Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied
Colorectal cancer, liver metastases

## Interventions
1. Rofecoxib 25 mg/day
2. Placebo

## Intervention Type
Other

## Phase
Not Specified

## Primary outcome measure
Not provided at time of registration

## Secondary outcome measures
Not provided at time of registration

## Overall study start date
01/01/1998

### Completion date
05/01/2002

## Eligibility

### Key inclusion criteria
1. Age greater than or equal to 18 years
2. Either sex
3. Liver resection deemed clinically appropriate for management of metastatic Colorectal Cancer (CRC) liver disease
4. Duration between decision to perform liver resection and surgery greater than 2 weeks
5. Ability to give written informed consent
6. Telephone at home

### Participant type(s)
Patient

### Age group
Adult

### Lower age limit
18 Years

### Sex
Both

### Target number of participants
Not provided at time of registration

### Key exclusion criteria
Not provided at time of registration

### Date of first enrolment
01/01/1998

### Date of final enrolment
05/01/2002

## Locations

### Countries of recruitment
England

United Kingdom

### Study participating centre
### UKCCCR Register Co-ordinator
London

United Kingdom
NW1 2DA

# Sponsor information

**Organisation**
Cancer Research UK (CRUK) (UK)

**Sponsor details**
PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

**Sponsor type**
Charity

**Website**
http://www.cancer.org.uk

**ROR**
https://ror.org/054225q67

# Funder(s)

**Funder type**
Industry

**Funder Name**
Merck and Co Inc. (USA)

# Results and Publications

**Publication and dissemination plan**
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/09/2003 | | Yes | No |